Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder characterized by the destruction of red blood cells (hemolysis) and subsequent release of hemoglobin into the urine, leading to its darkening, especially at night. It is associated with a disruption of complement regulation and the involvement of specific antigens on the surface of blood cells, such as CD55 and CD59, which are responsible for protecting red blood cells from complement attack. PNH is caused by a mutation in the PIGA gene, which is responsible for the synthesis of glycosylphosphatidylinositol (GPI), a molecule important for the binding of anticomplement proteins to the cell membrane. The disease can manifest itself with various clinical symptoms, including anemia, thrombocytopenia, and increased susceptibility to thrombosis, making it a serious problem for both patients and physicians.
History of the disease and interesting historical facts
Paroxysmal nocturnal hemoglobinuria was first described in the early 19th century, but it was not until the 20th century that the disease was thoroughly studied. In 1882, the German physician K. M. Nowan wrote a detailed description of hemoglobinuria caused by malaria, but later cases associated with PNH were clearly distinguished. In the 1960s, it was shown that the disease is associated with inherited changes at the level of the cell membrane. Epidemiological studies conducted in the 1980s established a link between PNH and the risk of thrombosis, which significantly influenced approaches to the treatment and monitoring of these patients. Interesting facts include that PNH was called "nocturnal" because symptoms tend to worsen in the evening and at night, when it is especially difficult for women and men to avoid exacerbations of the disease.
Epidemiology
The epidemiology of PNH shows that this disease is extremely rare. According to various studies, the incidence is approximately 1-5 cases per million people per year. Rates may vary depending on the population and geographic area. Based on the literature, PNH is more common in adults, especially in men aged 30 to 50 years. Along with the low incidence, the disease has a high probability of developing vascular complications, which makes it especially dangerous. Interestingly, in some populations suffering from genetic disorders, such as sideroblastic anemia, the incidence may be higher, indicating possible underlying mechanisms contributing to the development of PNH.
Genetic predisposition to this disease
Paroxysmal nocturnal hemoglobinuria results from a mutation in the PIGA gene, which results in a disruption of the synthesis of GPI-anchor proteins. These mutations can be spontaneous, but a predisposition is also observed in some cases of familial inheritance. It is also known that other genetic mechanisms can influence the progression of the disease, since heteroallelic mutations in other genes, such as CD55 and CD59, can impair the protective functions of red blood cells. Modern molecular methods make it possible to identify these mutations and determine the risk of developing PNH in patients with a predisposition. Data on genetic markers can help physicians in a personalized approach to treatment and monitoring of the progressive disease.
Risk factors for the development of this disease
Risk factors that contribute to the development of PNH can be both congenital and acquired. The main risk factors include:
- Physical factors: significant physical activity, trauma and surgery, which can trigger the activation of the infection and worsen symptoms.
- Chemical factors: exposure to certain drugs, such as antibiotics and chemotherapy drugs, which can cause hemolysis.
- Infectious diseases: Some viral infections, such as virus C, may affect the level of hemolysis and are associated with relapses.
- Associated diseases: the presence of autoimmune diseases and other disorders of the hemostasis system can also increase the risk of developing PNH base.
Diagnosis of this disease
Diagnosis of PNH requires a comprehensive approach, including clinical and laboratory studies. The main symptoms of the disease include:
- Dark urine, especially at night.
- Symptoms of anemia: shortness of breath, fatigue, pale skin.
- Thrombocytopenia and increased susceptibility to thrombosis.
In laboratory practice, the following are used to diagnose PNH:
- Complete blood count to determine hemoglobin, platelet and reticulocyte levels.
- Biochemical blood test to assess liver and kidney function.
- Lactate dehydrogenase (LDH) and bilirubin levels.
- Test for the presence of hemoglobin in urine.
- Specific tests to determine the presence of GPI anchor proteins.
Radiological studies such as abdominal ultrasound may be used to evaluate internal organs and detect possible thrombus formation. Differential diagnosis includes exclusion of other forms of hemolysis such as sickle cell disease, talented anemia, and autoimmune conditions.
Treatment
Treatment of paroxysmal nocturnal hemoglobinuria should be individualized and may include the following approaches:
- General treatment: correction of anemia by blood transfusions, especially in acute cases.
- Pharmacological treatment: use of extrahemolytic drugs such as erythropoietin and glucocorticosteroids to reduce hemolysis and increase hemoglobin levels.
- Surgical treatment: In particularly severe cases, selective splenectomy may be considered, especially if multiple thrombi develop.
- Other treatments: The use of polyclonal antibodies may help modify the immune response.
List of medications used to treat this disease
List of the most common drugs used in the treatment of PNH:
- Erythropoietin - to stimulate the production of red blood cells.
- Glucocorticosteroids - to suppress the immune response.
- Antibiotics - to prevent infectious complications.
- Blood thinners (anticoagulants) - to prevent blood clots.
Disease monitoring
Monitoring patients with PNH requires regular monitoring of various clinical and laboratory parameters. Key monitoring steps include:
- Regular blood tests to assess hemoglobin and platelet levels.
- Evaluation of kidney and liver function.
- Monitoring for the presence of thrombus formation using ultrasound or other imaging techniques.
The prognosis of the disease depends on early diagnosis and individualized treatment. Complications of PNH may include thrombosis, which is potentially life-threatening for patients, making monitoring a constant necessity.
Age-related features of the disease
Paroxysmal nocturnal hemoglobinuria may present differently in different age groups. In children, PNH is extremely rare, and symptoms may often be less severe. In adults, the disease is more common in the 30-50 age group, with a severe course and a high risk of thrombosis. In older people, PNH presents with more severe symptoms of hemolysis and may be associated with other comorbidities, such as vascular disorders.
Questions and Answers
- What is paroxysmal nocturnal hemoglobinuria? - This is a rare disease characterized by the destruction of red blood cells and the release of hemoglobin into the urine, which leads to a change in the color of the urine, especially at night.
- What are the main symptoms of PNH? - Dark urine, fatigue, shortness of breath, thrombocytopenia and increased susceptibility to thrombosis.
- What are the risk factors associated with PNH? - Physical activity, injuries, exposure to chemicals and the presence of infectious diseases.
- How is PNH diagnosed? — Diagnostics include general and biochemical blood tests, urine hemoglobin tests and specific tests for GPI-anchor proteins.
- How is PNH treated? — Treatment may include blood transfusions, erythropoietin, glucocorticosteroids, and, in severe cases, surgery.
